Annual Accounts Payable
$1.96 M
-$8.58 M-81.37%
December 31, 2023
Summary
- As of February 26, 2025, SUPN annual accounts payable is $1.96 million, with the most recent change of -$8.58 million (-81.37%) on December 31, 2023.
- During the last 3 years, SUPN annual accounts payable has fallen by -$4.18 million (-68.05%).
- SUPN annual accounts payable is now -83.30% below its all-time high of $11.76 million, reached on December 31, 2011.
Performance
SUPN Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Accounts Payable
$6.39 M
+$1.76 M+38.12%
September 30, 2024
Summary
- As of February 26, 2025, SUPN quarterly accounts payable is $6.39 million, with the most recent change of +$1.76 million (+38.12%) on September 30, 2024.
- Over the past year, SUPN quarterly accounts payable has increased by +$3.00 million (+88.61%).
- SUPN quarterly accounts payable is now -82.00% below its all-time high of $35.52 million, reached on June 30, 2022.
Performance
SUPN Quarterly Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Accounts Payable Formula
Accounts Payable = Beginning Accounts Payable + Purchases on Credit − Payments to Suppliers
SUPN Accounts Payable Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -81.4% | +88.6% |
| 3 y3 years | -68.0% | +88.6% |
| 5 y5 years | -38.5% | +88.6% |
SUPN Accounts Payable Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -81.4% | at low | -82.0% | +225.5% |
| 5 y | 5-year | -81.4% | at low | -82.0% | +225.5% |
| alltime | all time | -83.3% | +5.4% | -82.0% | +644.1% |
Supernus Pharmaceuticals Accounts Payable History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $6.39 M(+38.1%) |
| Jun 2024 | - | $4.63 M(-67.9%) |
| Mar 2024 | - | $14.40 M(+633.0%) |
| Dec 2023 | $1.96 M(-81.4%) | $1.96 M(-42.0%) |
| Sep 2023 | - | $3.39 M(-23.0%) |
| Jun 2023 | - | $4.40 M(-61.9%) |
| Mar 2023 | - | $11.54 M(+9.5%) |
| Dec 2022 | $10.54 M(+13.0%) | $10.54 M(-34.2%) |
| Sep 2022 | - | $16.02 M(-54.9%) |
| Jun 2022 | - | $35.52 M(+188.2%) |
| Mar 2022 | - | $12.32 M(+32.1%) |
| Dec 2021 | $9.33 M(+51.8%) | $9.33 M(+2.3%) |
| Sep 2021 | - | $9.13 M(+26.2%) |
| Jun 2021 | - | $7.23 M(+21.4%) |
| Mar 2021 | - | $5.95 M(-3.1%) |
| Dec 2020 | $6.15 M(-39.4%) | $6.15 M(-45.1%) |
| Sep 2020 | - | $11.19 M(+103.0%) |
| Jun 2020 | - | $5.51 M(+76.5%) |
| Mar 2020 | - | $3.12 M(-69.2%) |
| Dec 2019 | $10.14 M(+217.4%) | $10.14 M(+228.2%) |
| Sep 2019 | - | $3.09 M(-24.3%) |
| Jun 2019 | - | $4.08 M(-43.6%) |
| Mar 2019 | - | $7.24 M(+126.6%) |
| Dec 2018 | $3.19 M(-53.3%) | $3.19 M(-67.5%) |
| Sep 2018 | - | $9.84 M(+234.3%) |
| Jun 2018 | - | $2.94 M(-11.7%) |
| Mar 2018 | - | $3.33 M(-51.3%) |
| Dec 2017 | $6.84 M | $6.84 M(+9.3%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2017 | - | $6.26 M(-17.4%) |
| Jun 2017 | - | $7.58 M(+49.9%) |
| Mar 2017 | - | $5.06 M(-37.2%) |
| Dec 2016 | $8.05 M(+86.7%) | $8.05 M(+200.0%) |
| Sep 2016 | - | $2.69 M(+19.7%) |
| Jun 2016 | - | $2.24 M(-15.2%) |
| Mar 2016 | - | $2.65 M(-38.7%) |
| Dec 2015 | $4.31 M(+131.6%) | $4.31 M(+53.4%) |
| Sep 2015 | - | $2.81 M(-37.8%) |
| Jun 2015 | - | $4.52 M(+426.0%) |
| Mar 2015 | - | $859.00 K(-53.9%) |
| Dec 2014 | $1.86 M(-40.7%) | $1.86 M(-91.5%) |
| Sep 2014 | - | $21.98 M(+15.4%) |
| Jun 2014 | - | $19.04 M(+29.9%) |
| Mar 2014 | - | $14.66 M(+366.5%) |
| Dec 2013 | $3.14 M(-70.5%) | $3.14 M(-78.3%) |
| Sep 2013 | - | $14.47 M(+23.4%) |
| Jun 2013 | - | $11.73 M(+7.6%) |
| Mar 2013 | - | $10.90 M(+2.2%) |
| Dec 2012 | $10.67 M(-9.3%) | $10.67 M(+1.7%) |
| Sep 2012 | - | $10.48 M(+14.3%) |
| Jun 2012 | - | $9.18 M(-1.7%) |
| Mar 2012 | - | $9.34 M(-20.6%) |
| Dec 2011 | $11.76 M(+4.4%) | $11.76 M(+28.6%) |
| Sep 2011 | - | $9.15 M(-18.8%) |
| Dec 2010 | $11.26 M(+80.4%) | $11.26 M(-20.1%) |
| Sep 2010 | - | $14.09 M(+125.7%) |
| Dec 2009 | $6.25 M(+39.8%) | $6.25 M |
| Dec 2008 | $4.47 M | - |
FAQ
- What is Supernus Pharmaceuticals annual accounts payable?
- What is the all time high annual accounts payable for Supernus Pharmaceuticals?
- What is Supernus Pharmaceuticals annual accounts payable year-on-year change?
- What is Supernus Pharmaceuticals quarterly accounts payable?
- What is the all time high quarterly accounts payable for Supernus Pharmaceuticals?
- What is Supernus Pharmaceuticals quarterly accounts payable year-on-year change?
What is Supernus Pharmaceuticals annual accounts payable?
The current annual accounts payable of SUPN is $1.96 M
What is the all time high annual accounts payable for Supernus Pharmaceuticals?
Supernus Pharmaceuticals all-time high annual accounts payable is $11.76 M
What is Supernus Pharmaceuticals annual accounts payable year-on-year change?
Over the past year, SUPN annual accounts payable has changed by -$8.58 M (-81.37%)
What is Supernus Pharmaceuticals quarterly accounts payable?
The current quarterly accounts payable of SUPN is $6.39 M
What is the all time high quarterly accounts payable for Supernus Pharmaceuticals?
Supernus Pharmaceuticals all-time high quarterly accounts payable is $35.52 M
What is Supernus Pharmaceuticals quarterly accounts payable year-on-year change?
Over the past year, SUPN quarterly accounts payable has changed by +$3.00 M (+88.61%)